Metabolic and toxicological considerations for diuretic therapy in patients with acute heart failure

Bibliography

• Lloyd-Jones D, Adams RJ, Brown TM, ; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Executive summary: heart disease and stroke statistics–2010 update: a report from the American Heart Association. Circulation 2010;121:948-54
   PubMed Web of Science ®Google Scholar
• Ahmed A, Allman RM, Fonarow GC, Incident heart failure hospitalization and subsequent mortality in chronic heart failure: a propensity-matched study. J Card Fail 2008;14:211-18
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Pang PS. Acute heart failure syndromes. J Am Coll Cardiol 2009;53:557-73
   PubMed Web of Science ®Google Scholar
• Felker GM, Leimberger JD, Califf RM, Risk stratification after hospitalization for decompensated heart failure. J Card Fail 2004;10:460-6
   PubMed Web of Science ®Google Scholar
• Lee DS, Austin PC, Rouleau JL, Predicting mortality among patients hospitalized for heart failure: derivation and validation of a clinical model. JAMA 2003;290:2581-7
   PubMed Web of Science ®Google Scholar
• Adams KF Jr, Fonarow GC, Emerman CL, ; ADHERE Scientific Advisory Committee and Investigators. Characteristics and outcomes of patients hospitalized for heart failure in the United States: rationale, design, and preliminary observations from the first 100,000 cases in the Acute Decompensated Heart Failure National Registry (ADHERE). Am Heart J 2005;149:209-16
   PubMed Web of Science ®Google Scholar
• Mebazaa A, Gheorghiade M, Pina IL, Practical recommendations for prehospital and early in-hospital management of patients presenting with acute heart failure syndromes. Crit Care Med 2008;36(1 Suppl):S129-39
   PubMedGoogle Scholar
• Gheorghiade M, Zannad F, Sopko G, ; International Working Group on Acute Heart Failure Syndromes. Acute heart failure syndromes: current state and framework for future research. Circulation 2005;112:3958-68
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Follath F, Ponikowski P, Assessing and grading congestion in acute heart failure: a scientific statement from the Acute Heart Failure Committee of the Heart Failure Association of the European Society of Cardiology and endorsed by the European Society of Intensive Care Medicine. Eur J Heart Fail 2010;12:423-33
   PubMed Web of Science ®Google Scholar
• Harrison-Bernard LM. The renal renin-angiotensin system. Adv Physiol Educ 2009;33:270-4
   PubMed Web of Science ®Google Scholar
• Schrier RW, Abraham WT. Hormones and hemodynamics in heart failure. N Engl J Med 1999;341:577-85
   PubMed Web of Science ®Google Scholar
• Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (first of two parts). N Engl J Med 1975;292:81-8
   PubMed Web of Science ®Google Scholar
• Schrier RW, Berl T. Nonosmolar factors affecting renal water excretion (second of two parts). N Engl J Med 1975;292:141-5
   PubMed Web of Science ®Google Scholar
• Clayton SC, Haack KK, Zucker IH. Renal denervation modulates angiotensin receptor expression in the renal cortex of rabbits with chronic heart failure. Am J Physiol Renal Physiol 2011;300(9):F31-9
   PubMedGoogle Scholar
• Zucker IH, Schultz HD, Patel KP, Regulation of central angiotensin type 1 receptors and sympathetic outflow in heart failure. Am J Physiol Heart Circ Physiol 2009;297(5):H1557-66
   PubMed Web of Science ®Google Scholar
• Schrier RW, Ohara M, Rogachev B, Aquaporin-2 water channels and vasopressin antagonists in edematous disorders. Mol Genet Metab 1998;65:255-63
   PubMed Web of Science ®Google Scholar
• Schrier RW, Cadnapaphornchai MA, Ohara M. Water retention and aquaporins in heart failure, liver disease and pregnancy. J R Soc Med 2001;94:265-9
   PubMed Web of Science ®Google Scholar
• Dickstein K, Cohen-Solal A, Filippatos G, ESC guidelines for the diagnosis and treatment of acute and chronic heart failure 2008: the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur J Heart Fail 2008;10:933-89
   PubMed Web of Science ®Google Scholar
• Nieminen MS, Brutsaert D, Dickstein K, EuroHeart Failure Survey II (EHFS II): a survey on hospitalized acute heart failure patients: description of population. Eur Heart J 2006;27:2725-36
   PubMed Web of Science ®Google Scholar
• Peacock WF, Costanzo MR, De Marco T, ; ADHERE Scientific Advisory Committee and Investigators. Impact of intravenous loop diuretics on outcomes of patients hospitalized with acute decompensated heart failure: insights from the ADHERE registry. Cardiology 2009;113:12-19
   PubMed Web of Science ®Google Scholar
• ADHERE Registry [database] First quarter 2003 benchmark report. Sunnyvale, CA: Scios, Inc., Jan 2003
   Google Scholar
• Stevenson LW, Bellil D, Grover-McKay M, Effects of afterload reduction (diuretics and vasodilators) on left ventricular volume and mitral regurgitation in severe congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol 1987;60:654-8
   PubMed Web of Science ®Google Scholar
• Butler J, Forman DE, Abraham WT, Relationship between heart failure treatment and development of worsening renal function among hospitalized patients. Am Heart J 2004;147:331-8
   PubMed Web of Science ®Google Scholar
• Metra M, Nodari S, Parrinello G, Worsening renal function in patients hospitalised for acute heart failure: clinical implications and prognostic significance. Eur J Heart Fail 2008;10:188-95
   PubMed Web of Science ®Google Scholar
• Nohria A, Hasselblad V, Stebbins A, Cardiorenal interactions: insights from the ESCAPE trial. J Am Coll Cardiol 2008;51:1268-74
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Francis GS, Importance of venous congestion for worsening of renal function in advanced decompensated heart failure. J Am Coll Cardiol 2009;53:589-96
   PubMed Web of Science ®Google Scholar
• Blake WD, Wegria R, Keating RP, Ward HP. Effect of increased renal venous pressure on renal function. Am J Physiol 1949;157:1-13
   PubMed Web of Science ®Google Scholar
• Mullens W, Abrahams Z, Skouri HN, Elevated intra-abdominal pressure in acute decompensated heart failure: a potential contributor to worsening renal function? J Am Coll Cardiol 2008;51:300-6
   PubMed Web of Science ®Google Scholar
• Neuberg GW, Miller AB, O'Connor CM, PRAISE Investigators. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J 2002;144:31-8
   PubMed Web of Science ®Google Scholar
• Brater DC. Diuretic therapy. N Engl J Med 1998;339:387-95
   PubMed Web of Science ®Google Scholar
• Wang DJ, Gottlieb SS. Diuretics: still the mainstay of treatment. Crit Care Med 2008;36(1 Suppl):S89-94
   PubMedGoogle Scholar
• Ellison DH. Diuretic resistance: physiology and therapeutics. Semin Nephrol 1999;19:581-97
   PubMed Web of Science ®Google Scholar
• MacFadyen RJ, Gorski JC, Brater DC, Struthers AD. Furosemide responsiveness, non-adherence and resistance during the chronic treatment of heart failure: a longitudinal study. Br J Clin Pharmacol 2004;57:622-31
   PubMed Web of Science ®Google Scholar
• Petersen JS, DiBona GF. Effects of renal denervation on sodium balance and renal function during chronic furosemide administration in rats. J Pharmacol Exp Ther 1992;262:1103-9
   PubMed Web of Science ®Google Scholar
• Frolich JC, Hollifield JW, Dormois JC, Suppression of plasma renin activity by indomethacin in man. Circ Res 1976;39:447-52
   PubMed Web of Science ®Google Scholar
• Kaissling B, Stanton BA. Adaptation of distal tubule and collecting duct to increased sodium delivery. I. Ultrastructure. Am J Physiol 1988;255(6 Pt 2):F1256-68
   PubMed Web of Science ®Google Scholar
• Kaissling B, Bachmann S, Kriz W. Structural adaptation of the distal convoluted tubule to prolonged furosemide treatment. Am J Physiol 1985;248(3 Pt 2):F374-81
   PubMed Web of Science ®Google Scholar
• Wald H, Scherzer P, Popovtzer MM. Inhibition of thick ascending limb Na+-K+-ATPase activity in salt-loaded rats by furosemide. Am J Physiol 1989;256(4 Pt 2):F549-55
   PubMed Web of Science ®Google Scholar
• Hirsch AT, Pinto YM, Schunkert H, Dzau VJ. Potential role of the tissue renin-angiotensin system in the pathophysiology of congestive heart failure. Am J Cardiol 1990;66:22D-30D
   PubMed Web of Science ®Google Scholar
• McCurley JM, Hanlon SU, Wei SK, Furosemide and the progression of left ventricular dysfunction in experimental heart failure. J Am Coll Cardiol 2004;44:1301-7
   PubMed Web of Science ®Google Scholar
• Wilcox CS, Mitch WE, Kelly RA, Response of the kidney to furosemide. I. Effects of salt intake and renal compensation. J Lab Clin Med 1983;102:450-8
   PubMed Web of Science ®Google Scholar
• Loon NR, Wilcox CS, Unwin RJ. Mechanism of impaired natriuretic response to furosemide during prolonged therapy. Kidney Int 1989;36:682-9
   PubMed Web of Science ®Google Scholar
• Asare K. Management of loop diuretic resistance in the intensive care unit. Am J Health Syst Pharm 2009;66:1635-40
   PubMed Web of Science ®Google Scholar
• Paterna S, Di Pasquale P, Parrinello G, Changes in brain natriuretic peptide levels and bioelectrical impedance measurements after treatment with high-dose furosemide and hypertonic saline solution versus high-dose furosemide alone in refractory congestive heart failure: a double-blind study. J Am Coll Cardiol 2005;45:1997-2003
   PubMed Web of Science ®Google Scholar
• Testani JM, Chen J, McCauley BD, Potential effects of aggressive decongestion during the treatment of decompensated heart failure on renal function and survival. Circulation 2010;122:265-72
   PubMed Web of Science ®Google Scholar
• Kiyingi A, Field MJ, Pawsey CC, Metolazone in treatment of severe refractory congestive cardiac failure. Lancet 1990;335:29-31
   PubMed Web of Science ®Google Scholar
• Bowling CB, Pitt B, Ahmed MI, Hypokalemia and outcomes in patients with chronic heart failure and chronic kidney disease: findings from propensity-matched studies. Circ Heart Fail 2010;3(2):253-60
   PubMed Web of Science ®Google Scholar
• Maisel AS, Peacock WF, McMullin N, Timing of immunoreactive B-type natriuretic peptide levels and treatment delay in acute decompensated heart failure: an ADHERE (Acute Decompensated Heart Failure National Registry) analysis. J Am Coll Cardiol 2008;52:534-40
   PubMed Web of Science ®Google Scholar
• Philbin EF, Cotto M, Rocco TA Jr, Jenkins PL. Association between diuretic use, clinical response, and death in acute heart failure. Am J Cardiol 1997;80:519-22
   PubMed Web of Science ®Google Scholar
• Hasselblad V, Gattis Stough W, Shah MR, Relation between dose of loop diuretics and outcomes in a heart failure population: results of the ESCAPE trial. Eur J Heart Fail 2007;9:1064-9
   PubMed Web of Science ®Google Scholar
• Domanski M, Norman J, Pitt B, Diuretic use, progressive heart failure, and death in patients in the Studies Of Left Ventricular Dysfunction (SOLVD). J Am Coll Cardiol 2003;42:705-8
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Cruz DN, Aspromonte N, ; Acute Dialysis Quality Initiative Consensus Group. Epidemiology of cardio-renal syndromes: workgroup statements from the 7th ADQI Consensus Conference. Nephrol Dial Transplant 2010;25:1406-16
   PubMed Web of Science ®Google Scholar
• Damman K, Navis G, Smilde TD, Decreased cardiac output, venous congestion and the association with renal impairment in patients with cardiac dysfunction. Eur J Heart Fail 2007;9:872-8
   PubMed Web of Science ®Google Scholar
• Ronco C, McCullough P, Anker SD, ; Acute Dialysis Quality Initiative (ADQI) Consensus Group. Cardio-renal syndromes: report from the consensus conference of the acute dialysis quality initiative. Eur Heart J 2010;31:703-11
   PubMed Web of Science ®Google Scholar
• Cowie MR, Komajda M, Murray-Thomas T, ; POSH Investigators. Prevalence and impact of worsening renal function in patients hospitalized with decompensated heart failure: results of the prospective outcomes study in heart failure (POSH). Eur Heart J 2006;27:1216-22
   PubMed Web of Science ®Google Scholar
• Forman DE, Butler J, Wang Y, Incidence, predictors at admission, and impact of worsening renal function among patients hospitalized with heart failure. J Am Coll Cardiol 2004;43:61-7
   PubMed Web of Science ®Google Scholar
• Martinez-Maldonado M, Cordova HR. Cellular and molecular aspects of the renal effects of diuretic agents. Kidney Int 1990;38:632-41
   PubMed Web of Science ®Google Scholar
• Nielsen S, Maunsbach AB, Ecelbarger CA, Knepper MA. Ultrastructural localization of Na-K-2Cl cotransporter in thick ascending limb and macula densa of rat kidney. Am J Physiol 1998;275(6 Pt 2):F885-93
   PubMed Web of Science ®Google Scholar
• Brezis M, Agmon Y, Epstein FH. Determinants of intrarenal oxygenation. I. Effects of diuretics. Am J Physiol 1994;267(6 Pt 2):F1059-62
   PubMed Web of Science ®Google Scholar
• Peterson OW, Gabbai FB, Myers RR, A single nephron model of acute tubular injury: role of tubuloglomerular feedback. Kidney Int 1989;36:1037-44
   PubMed Web of Science ®Google Scholar
• Pickkers P, Dormans TP, Russel FG, Direct vascular effects of furosemide in humans. Circulation 1997;96:1847-52
   PubMed Web of Science ®Google Scholar
• Francis GS, Siegel RM, Goldsmith SR, Acute vasoconstrictor response to intravenous furosemide in patients with chronic congestive heart failure. Activation of the neurohumoral axis. Ann Intern Med 1985;103:1-6
   PubMed Web of Science ®Google Scholar
• Brater DC, Chennavasin P, Seiwell R. Furosemide in patients with heart failure: shift in dose-response curves. Clin Pharmacol Ther 1980;28:182-6
   PubMed Web of Science ®Google Scholar
• Brater DC, Chennavasin P, Day B, Bumetanide and furosemide. Clin Pharmacol Ther 1983;34:207-13
   PubMed Web of Science ®Google Scholar
• Beermann B. Aspects on pharmacokinetics of some diuretics. Acta Pharmacol Toxicol (Copenh) 1984;54(Suppl 1):17-29
   PubMedGoogle Scholar
• Brater DC, Day B, Burdette A, Anderson S. Bumetanide and furosemide in heart failure. Kidney Int 1984;26:183-9
   PubMed Web of Science ®Google Scholar
• Brater DC, Leinfelder J, Anderson SA. Clinical pharmacology of torasemide, a new loop diuretic. Clin Pharmacol Ther 1987;42:187-92
   PubMed Web of Science ®Google Scholar
• Howard PA, Dunn MI. Effectiveness of continuous infusions of loop diuretics for severe heart failure. J Cardiovasc Med (Hagerstown) 2006;7:5-10
   PubMed Web of Science ®Google Scholar
• Van Meyel JJ, Smits P, Dormans T, Continuous infusion of furosemide in the treatment of patients with congestive heart failure and diuretic resistance. J Intern Med 1994;235:329-34
   PubMed Web of Science ®Google Scholar
• Rudy DW, Voelker JR, Greene PK, Loop diuretics for chronic renal insufficiency: a continuous infusion is more efficacious than bolus therapy. Ann Intern Med 1991;115:360-6
   PubMed Web of Science ®Google Scholar
• Magovern JA, Magovern GJ Jr. Diuresis in hemodynamically compromised patients: continuous furosemide infusion. Ann Thorac Surg 1990;50:482-4
   PubMed Web of Science ®Google Scholar
• Copeland JG, Campbell DW, Plachetka JR, Diuresis with continuous infusion of furosemide after cardiac surgery. Am J Surg 1983;146:796-9
   PubMed Web of Science ®Google Scholar
• Lawson DH, Gray JM, Henry DA, Tillstone WJ. Continuous infusion of frusemide in refractory oedema. Br Med J 1978;2:476
   PubMed Web of Science ®Google Scholar
• Salvador DR, Rey NR, Ramos GC, Punzalan FE. Continuous infusion versus bolus injection of loop diuretics in congestive heart failure. Cochrane Database Syst Rev 2005(3):CD003178
   Google Scholar
• Allen LA, Turer AT, Dewald T, Continuous versus bolus dosing of furosemide for patients hospitalized for heart failure. Am J Cardiol 2010;105:1794-7
   PubMed Web of Science ®Google Scholar
• Felker GM, Lee KL, Bull DA, Diuretic strategies in patients with acute decompensated heart failure. N Engl J Med 2011;364(9):797-805
   PubMed Web of Science ®Google Scholar
• Lopez B, Querejeta R, Gonzalez A, Effects of loop diuretics on myocardial fibrosis and collagen type I turnover in chronic heart failure. J Am Coll Cardiol 2004;43:2028-35
   PubMed Web of Science ®Google Scholar
• Lopez B, Querejeta R, Gonzalez A, Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009;53:236-42
   PubMed Web of Science ®Google Scholar
• Kasama S, Toyama T, Hatori T, Effects of torasemide on cardiac sympathetic nerve activity and left ventricular remodelling in patients with congestive heart failure. Heart 2006;92:1434-40
   PubMed Web of Science ®Google Scholar
• Howard PA, Dunn MI. Aggressive diuresis for severe heart failure in the elderly. Chest 2001;119:807-10
   PubMed Web of Science ®Google Scholar
• Ali SS, Olinger CC, Sobotka PA, Loop diuretics can cause clinical natriuretic failure: a prescription for volume expansion. Congest Heart Fail 2009;15:1-4
   PubMedGoogle Scholar
• Morgan DB, Davidson C. Hypokalaemia and diuretics: an analysis of publications. Br Med J 1980;280:905-8
   PubMed Web of Science ®Google Scholar
• Ellison DH. Diuretic therapy and resistance in congestive heart failure. Cardiology 2001;96:132-43
   PubMed Web of Science ®Google Scholar
• Ellison DH. Diuretic drugs and the treatment of edema: from clinic to bench and back again. Am J Kidney Dis 1994;23:623-43
   PubMed Web of Science ®Google Scholar
• Quamme GA. Effect of furosemide on calcium and magnesium transport in the rat nephron. Am J physiol 1981;241:F340-7
   PubMed Web of Science ®Google Scholar
• Dorup I, Skajaa K, Clausen T, Kjeldsen K. Reduced concentrations of potassium, magnesium, and sodium-potassium pumps in human skeletal muscle during treatment with diuretics. Br Med J (Clin Res ED) 1988;296:455-8
   PubMed Web of Science ®Google Scholar
• Wigand ME, Heidland A. Ototoxic side-effects of high doses of frusemide in patients with uraemia. Postgrad Med J 1971;47(Suppl):54-6
   PubMedGoogle Scholar
• Pitt B, Zannad F, Remme WJ, The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators. N Engl J Med 1999;341:709-17
   PubMed Web of Science ®Google Scholar
• Pitt B, Remme W, Zannad F, Eplerenone Post-Acute Myocardial Infarction Heart Failure Efficacy and Survival Study Investigators. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003;348:1309-21
   PubMed Web of Science ®Google Scholar
• Mizuno Y, Yoshimura M, Yasue H, Aldosterone production is activated in failing ventricle in humans. Circulation 2001;103:72-7
   PubMed Web of Science ®Google Scholar
• Ramires FJ, Mansur A, Coelho O, Effect of spironolactone on ventricular arrhythmias in congestive heart failure secondary to idiopathic dilated or to ischemic cardiomyopathy. Am J Cardiol 2000;85:1207-11
   PubMed Web of Science ®Google Scholar
• Palmer BF. Managing hyperkalemia caused by inhibitors of the renin-angiotensin-aldosterone system. N Engl J Med 2004;351:585-92
   PubMed Web of Science ®Google Scholar
• Mehta RL, Pascual MT, Soroko S, PICARD Study Group. Diuretics, mortality, and nonrecovery of renal function in acute renal failure. JAMA 2002;288:2547-53
   PubMed Web of Science ®Google Scholar
• Bagshaw SM, Delaney A, Haase M, Loop diuretics in the management of acute renal failure: a systematic review and meta-analysis. Crit Care Resusc 2007;9:60-8
   PubMedGoogle Scholar
• Ho KM, Sheridan DJ. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006;333:420
   PubMed Web of Science ®Google Scholar
• Logeart D, Tabet JY, Hittinger L, Transient worsening of renal function during hospitalization for acute heart failure alters outcome. Int J Cardiol 2008;127:228-32
   PubMed Web of Science ®Google Scholar
• Latchamsetty R, Fang J, Kline-Rogers E, Prognostic value of transient and sustained increase in in-hospital creatinine on outcomes of patients admitted with acute coronary syndrome. Am J Cardiol 2007;99:939-42
   PubMed Web of Science ®Google Scholar
• de Silva R, Nikitin NP, White KK, Incidence of renal dysfunction over 6 months in patients with chronic heart failure due to left ventricular systolic dysfunction: contributing factors and relationship to prognosis. Eur Heart J 2006;27:569-81
   PubMed Web of Science ®Google Scholar
• Androne AS, Hryniewicz K, Hudaihed A, Relation of unrecognized hypervolemia in chronic heart failure to clinical status, hemodynamics, and patient outcomes. Am J Cardiol 2004;93:1254-9
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N, Giovinazzo P, B-type natriuretic peptide-guided treatment for predicting outcome in patients hospitalized in sub-intensive care unit with acute heart failure. J Card Fail 2008;14:219-24
   PubMed Web of Science ®Google Scholar
• Valle R, Aspromonte N. Use of brain natriuretic peptide and bioimpedance to guide therapy in heart failure patients. Contrib Nephrol 2010;164:209-16
   PubMed Web of Science ®Google Scholar
• Konstam MA, Gheorghiade M, Burnett JC Jr, ; Efficacy of Vasopressin Antagonism in Heart Failure Outcome Study With Tolvaptan (EVEREST) Investigators. Effects of oral tolvaptan in patients hospitalized for worsening heart failure: the EVEREST Outcome Trial. JAMA 2007;297(12):1319-31
   PubMed Web of Science ®Google Scholar
• Udelson JE, Smith WB, Hendrix GH, Acute hemodynamic effects of conivaptan, a dual V1A and V2 vasopressin receptor antagonist, in patients with advanced heart failure. Circulation 2001;104:2417-23
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Niazi I, Ouyang J, Vasopressin V2-receptor blockade with tolvaptan in patients with chronic heart failure: results from a double-blind, randomized trial. Circulation 2003;107:2690-6
   PubMed Web of Science ®Google Scholar
• Gheorghiade M, Gattis WA, O'Connor CM, ; Acute and Chronic Therapeutic Impact of a Vasopressin Antagonist in Congestive Heart Failure (ACTIV in CHF) Investigators. Effects of tolvaptan, a vasopressin antagonist, in patients hospitalized with worsening heart failure: a randomized controlled trial. JAMA 2004;291:1963-71
   PubMed Web of Science ®Google Scholar
• Modlinger PS, Welch WJ. Adenosine A1 receptor antagonists and the kidney. Curr Opin Nephrol Hypertens 2003;12:497-502
   PubMed Web of Science ®Google Scholar
• Gottlieb SS. Renal effects of adenosine A1-receptor antagonists in congestive heart failure. Drugs 2001;61:1387-93
   PubMed Web of Science ®Google Scholar
• Massie BM, O'Connor CM, Metra M, ; PROTECT Investigators and Committees. Rolofylline, an adenosine A1-receptor antagonist, in acute heart failure. N Engl J Med 2010;363:1419-28
   PubMed Web of Science ®Google Scholar
• Bart BA, Boyle A, Bank AJ, Ultrafiltration versus usual care for hospitalized patients with heart failure: the Relief for Acutely Fluid-Overloaded Patients With Decompensated Congestive Heart Failure (RAPID-CHF) trial. J Am Coll Cardiol 2005;46:2043-6
   PubMed Web of Science ®Google Scholar
• Costanzo MR, Guglin ME, Saltzberg MT, ; UNLOAD Trial Investigators. Ultrafiltration versus intravenous diuretics for patients hospitalized for acute decompensated heart failure. J Am Coll Cardiol 2007;49:675-83
   PubMed Web of Science ®Google Scholar
• Agostoni P, Marenzi G, Lauri G, Sustained improvement in functional capacity after removal of body fluid with isolated ultrafiltration in chronic cardiac insufficiency: failure of furosemide to provide the same result. Am J Med 1994;96(3):191-9
   PubMed Web of Science ®Google Scholar